Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT01400555 is registered in ClinicalTrials.gov with Cougar Biotechnology, Inc. as lead sponsor.

NCT NCT01400555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01400555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Cougar Biotechnology, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2011
Completion date
February 28, 2017
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate neoplasms